艾美疫苗(06660.HK) 公布,集团第二代高效价吸附破伤风疫苗已获国家药品监督管理局《药物临床试验批准通知书》,标志该疫苗的研发进入了新的阶段。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-19 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.